People · Operator
Named in public records as an officer, director or promoter · active 2010–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. | — | Biotechnology | Series C | $201.0M | $3.3B | 2010 |
| Miragen Therapeutics, Inc. | — | Biotechnology | Series C | $197.8M | $3.3B | 2010 |
Bruce S. Booth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bruce S. Booth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Booth | 2 | 12 |
| Peter Barrett | 1 | 18 |
| Jonathan Leff | 1 | 11 |
| Kyle Lefkoff | 1 | 9 |
| Mitchell S. Bloom | 1 | 7 |
| Mitchell Bloom | 1 | 6 |
| Kevin Starr | 1 | 5 |
| Jonathan Violin | 1 | 5 |
| Joseph L. Turner | 1 | 4 |
| THOMAS HUGHES | 1 | 4 |
| William S Marshall | 1 | 3 |
| Christopher J Morl | 1 | 3 |
| John S. Creecy | 1 | 3 |
| Frank E. Thomas | 1 | 3 |
| Lou Tartaglia | 1 | 3 |
| Bruce L Booth | 1 | 2 |
| John W Creecy | 1 | 2 |
| Frances Heller | 1 | 2 |
| Marvin Caruthers | 1 | 2 |
| Marvin H Caruthers | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.